The Impact of Additional Chromosomal Abnormalities in Response to Imatinib Mesylate Therapy for Chronic Myeloid Leukemia

Autores/as

  • Luize Otero Centro de Transplante de Medula Óssea (CEMO), Instituto Nacional de Câncer - (INCA) - Rio de Janeiro (RJ), Brasil. Programa de Pós-Graduação, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro - (UERJ) - Rio de Janeiro (RJ), Brasil
  • Maria Helena Ornellas Centro de Transplante de Medula Óssea (CEMO), Instituto Nacional de Câncer - (INCA) - Rio de Janeiro (RJ), Brasil. Departamento de Patologia, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro - (UERJ) - Rio de Janeiro (RJ), Brasil
  • Alexandre Mello de Azevedo Centro de Transplante de Medula Óssea (CEMO), Instituto Nacional de Câncer - (INCA) - Rio de Janeiro (RJ), Brasil
  • Jane Dobbin Setor de Hematologia, Instituto Nacional de Câncer - (INCA) - Rio de Janeiro (RJ), Brasil
  • Eliana Abdelhay Centro de Transplante de Medula Óssea (CEMO), Instituto Nacional de Câncer - (INCA) - Rio de Janeiro (RJ), Brasil
  • Luiz Fernando Bouzas Centro de Transplante de Medula Óssea (CEMO), Instituto Nacional de Câncer - (INCA) - Rio de Janeiro (RJ), Brasil
  • Teresa de Souza Fernandez Centro de Transplante de Medula Óssea (CEMO), Instituto Nacional de Câncer - (INCA) - Rio de Janeiro (RJ), Brasil

DOI:

https://doi.org/10.32635/2176-9745.RBC.2007v53n4.1770

Palabras clave:

Chronic myeloid leukemia, Imatinib, Chromosomal abnormalities

Resumen

Imatinib induces a complete cytogenetic response in more than 80% of newly diagnosed patients with chronic myeloid leukemia (CML) in the chronic phase (CP) and in 41% of patients in the first chronic phase after failure of interferon-α treatment. However, some patients do not respond completely. Therefore, according to most studies, drug resistance in CML patients treated with imatinib is correlated with cytogenetic abnormalities acquired during treatment. In this study we analyzed 48 CML patients treated with imatinib mesylate after interferon-_ resistance in order to elucidate the impact of additional chromosomal abnormalities prior to imatinib in response to therapy. Cytogenetic abnormalities in addition to the Philadelphia chromosome (Ph) were detected in 33.3% of patients. Patients with Ph as the sole cytogenetic abnormality prior to imatinib therapy presented a major cytogenetic response and significantly longer median overall survival (p=0.006) than patients with additional chromosomal abnormalities. Therefore, in this group of patients, another choice of treatment should be considered, such as stem cell transplantation or combination regimens as appropriate. The present study indicates the importance of detecting a double Ph chromosome prior to imatinib therapy. Patients showing this abnormality did not respond to imatinib, thus indicating the abnormality's association with resistance. Our study suggests that classical cytogenetic analysis is still an important tool prior to and during follow-up of CML patients treated with imatinib.

Descargas

Los datos de descargas todavía no están disponibles.

Descargas

Publicado

2007-12-31

Cómo citar

1.
Otero L, Ornellas MH, Azevedo AM de, Dobbin J, Abdelhay E, Bouzas LF, Fernandez T de S. The Impact of Additional Chromosomal Abnormalities in Response to Imatinib Mesylate Therapy for Chronic Myeloid Leukemia. Rev. Bras. Cancerol. [Internet]. 31 de diciembre de 2007 [citado 24 de diciembre de 2024];53(4):405-10. Disponible en: https://rbc.inca.gov.br/index.php/revista/article/view/1770

Número

Sección

ARTÍCULO ORIGINAL

Artículos más leídos del mismo autor/a